Antioxidant vitamins and lipid peroxidation in patients with rheumatoid arthritis: Association with inflammatory markers

Journal of Rheumatology

Volumn 29, Issue 11, 2002, Pages 2271-2277

  Paredes, Silvia ^a   Girona, Josefa ^a   Hurt Camejo, Eva ^a   Vallvé, Joan Carles ^a   Olivé, Silvia ^a   Heras, Mercedes ^a   Benito, Pere ^a   Masana, Lluís ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Cardiovascular diseases; Inflammation; Lipid peroxidation; Rheumatoid arthritis; Vitamins

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; ANTIOXIDANT; GLYCOSAMINOGLYCAN; HEMIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; RETINOL; VITAMIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATORY DISEASE; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTIOXIDANTS; ARTHRITIS, RHEUMATOID; CHOLESTEROL, LDL; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PROTEIN BINDING; VITAMIN A; VITAMIN E; VITAMINS;

EID: 0036842102     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Jacobsson LTH, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality: A longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53.
2. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomäki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995;22:1065-7.
4. Wallberg-Jonsson S, Öhman ML, Dahlqvist SR. Cardiovascular morbility and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
5. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol 1998;25:1072-7.
6. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: Have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
7. Rossner S, Löfmark C. Dyslipoproteinaemia in patients with active, chronic polyarthritis. A study on serum lipoproteins and trygliceride clearance. Atherosclerosis 1977;28:41-52.
8. Svenson KLC, Lithell H, Hällgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 1987;147:1912-6.
9. Park YB, Lee SK, Lee WK, et al. Lipid profile in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4.
10. Raynauld JP. Cardiovascular mortality in rheumatoid arthritis: How harmful are corticosteroids? [editorial]. J Rheumatol 1997;24:415-6.
11. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
12. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
13. Berliner JA, Navad M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
14. Girona J, La Ville AE, Heras M, Olivé S, Masana L. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-α secretion by THP-1 human macrophages. Free Radic Biol Med 1997;23:658-67.
15. Lunec J, Halloran SP, White AG, Dormandy TL. Free radical oxidation products in serum and synovial fluid in rheumatoid arthritis. J Rheumatol 1981;8:233-45.
16. Selley ML, Bourne DJ, Bartlett MR, et al. Occurrence of 4-hydroxy-2-nonenal in plasma and synovial fluid of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1992;51:481-4.
17. Pryor WA. Vitamin E and heart disease: Basic science to clinical intervention trials. Free Radic Biol Med 2000;28:141-64.
18. Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aromaa A. Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 1994;53:51-3.
19. Honkanen V, Konttinen YT, Mussalo-Rauhamaa H. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin Exp Rheumatol 1989;7:465-9.
20. Fairburn K, Grootveld M, Ward RJ, et al. α-tocopherol, lipids and lipoproteins in knee-joint synovial fluid and serum from patients with inflammatory joint disease. Clin Sci 1992;83:657-64.
21. Edmonds SE, Winyard PG, Guo R, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis 1997;56:649-55.
22. Wiedermann U, Chen XJ, Enerback L, Hanson LA, Kahu H, Dahlgren UI. Vitamin A deficiency increases inflammatory responses. Scand J Immunol 1996;44:578-84.
23. 2 production in macrophages from vitamin E treated rats. Prostaglandins Leukot Essent Fatty Acids 1991;4:89-92.
24. Pentland AP, Morrison AR, Jacobs SC, Hruza LL, Hebert JS, Packer L. Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. J Biol Chem 1992;267:15578-84.
25. 2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 1996;23:1162-6.
26. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
27. Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis. Arch Intern Med 2000;160:437-44.
28. 2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7.
29. 2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-4.
30. 2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res Cardiol 2000;95:413-7.
31. 2. Arterioscler Thromb Vasc Biol 2001;21:269-74.
32. 2 in normal and atherosclerotic arteries: Activity of the isolated enzyme on low density lipoprotein. Arterioscler Thromb Vasc Biol 1997;17:300-9.
33. 2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler Thromb Vasc Biol 2000;20:751-62.
34. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
35. Catignani GL, Bieri JG. Simultaneous determination of retinol and α-tocopherol in serum or plasma by liquid chromatography. Clin Chem 1983;29:708-12.
36. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol 1986;128:155-70.
37. Camejo G, Halberg C, Manschik-Lundin A, et al. Hemin binding and oxidation of lipoproteins in serum: Mechanisms and effect on the interaction of LDL with human macrophages. J Lipid Res 1998;39:755-65.
38. Hurt-Camejo E, Camejo G, Sartipy P. Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. In: Ordovas JM, editor. Lipoprotein Protocols. Totowa, NJ: Humana Press; 1998:267-79.
39. Jira W, Spiteller G, Richter A. Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 1997;87:81-9.
40. Halliwell B. Reactive oxygen species in living systems: Source, biochemistry, and role in human disease. Am J Med 1991;91:14S-22S.
41. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1993;52:677-80.
42. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
43. Esterbauer H, Ramos P. Chemistry and pathophysiology of oxidation of LDL. Rev Physiol Biochem Pharmacol 1995;127:31-64.
44. Yoshikawa T, Tanaka H, Kondo M. Lipid peroxidation in rat adjuvant arthritis and its inhibition by indomethacin. J Appl Biochem 1983;5:382-7.
45. Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992;22:172-80.
46. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26.
47. Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:443-7.
48. Hurt-Camejo E, Camejo G, Rosengreen B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31:1387-98.
49. Camejo G, Acquatella H, Laguna F. Interaction of low density lipoprotein with arterial proteoglycans: An additional risk factor? Atherosclerosis 1980;36:55-65.
50. Hurt-Camejo E, Camejo G, Rosengren B, et al. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 1992;12:569-83.